A phase I/IIa trial of VR 588 for the treatment of respiratory tract disordera
Phase of Trial: Phase I/II
Latest Information Update: 21 Mar 2017
At a glance
- Drugs VR 588 (Primary)
- Indications Respiratory tract disorders
- Focus Adverse reactions; First in man
- 21 Mar 2017 According to a Vectura media release, this trial is expected to begin in the 2H of 2017.
- 02 Dec 2016 New trial record
- 22 Nov 2016 According to a Vectura Group plc media release, this trial is expected to begin in the first half of 2017.